- 1European Patient Advocacy Institute, Riemerling, Germany
- 2VHL Europa, Vlaardingen, Netherlands
- 3Syreon Research Institute, Budapest, Hungary
- 4PNH Global Alliance, Tiel, Netherlands
- 5Workgroup of European Cancer Patient Advocacy Networks, Barcelona, Spain
- 6Myeloma Patients Europe, Brussels, Belgium
- 7European Sickle Cell Federation-ESCF, Dublin, Ireland
- 8Childhood Cancer International – Europe, Vienna, Austria
- 9University of Pécs Institute of Psychology, Pécs, Hungary
A Correction on
Methodological study protocol for the European Atlas of clinical trials in cancer and haematology
by Cases M, Giles R, Ágh T, Piggin M, Geissler J, Racovita M, Hagymásy J, Ruth Wogu L, Józwiak Á, Hyseni-Bocolli A, Hosszú D, Plate A and EuroACT Working Group (2025). Front. Pharmacol. 16:1558556. doi: 10.3389/fphar.2025.1558556
Authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú were erroneously assigned to affiliation 4 PNH Global Alliance, Tiel, Netherlands. This affiliation has now been removed for author Judit Hagymásy, Ákos Józwiak and Dalma Hosszú.
Affiliation 3 Syreon Research Institute, Budapest, Hungary was omitted for authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú. This affiliation has now been added for authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú.
The collaborative group EuroACT Working Group was erroneously not credited with authorship in the published article. The consortium should be credited with authorship.
The list of members of the EuroACT Working Group was omitted from the published article. The section Group Members of the EuroACT Working Group has been added to the article as follows: Attila Imre, Anna Bögös, Natacha Bolaños, Susanna Leto di Priolo, Kate Morgan.
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: cancer, haematology, rare disease, patient, patient reported outcome, clinical trials
Citation: Cases M, Giles R, Ágh T, Piggin M, Geissler J, Racovita M, Hagymásy J, Ruth Wogu L, Józwiak Á, Hyseni-Bocolli A, Hosszú D, Plate A and EuroACT Working Group (2025) Correction: Methodological study protocol for the European Atlas of clinical trials in cancer and haematology. Front. Pharmacol. 16:1743351. doi: 10.3389/fphar.2025.1743351
Received: 10 November 2025; Accepted: 11 November 2025;
Published: 21 November 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Cases, Giles, Ágh, Piggin, Geissler, Racovita, Hagymásy, Ruth Wogu, Józwiak, Hyseni-Bocolli, Hosszú, Plate and EuroACT Working Group. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mercè Cases, bWVyY2UuY2FzZXNAcGF0aWVudGFkdm9jYWN5LmV1; Rachel Giles, cmFjaGVsaGVsZW5naWxlc0BnbWFpbC5jb20=
†These authors have contributed equally to this work and share last authorship
Maria Piggin4